Immunotherapy with oligomannose-coated liposomes ameliorates allergic symptoms in a murine food allergy model
Original Articles

Title: Immunotherapy with oligomannose-coated liposomes ameliorates allergic symptoms in a murine food allergy model.

Short title: Immunotherapy with oligomannose-coated liposomes

Akiko Kawakita, Hisako Shirasaki, Motoko Yasutomi, Shuko Tokuriki, Mitsufumi Mayumi, Hironobu Naiki*, Yusei Ohshima,

Department of Pediatrics, Faculty of Medical Sciences, University of Fukui,

*Department of Pathology, Faculty of Medical Sciences, University of Fukui

Corresponding author: Yusei Ohshima, MD, PhD.

Department of Pediatrics, Faculty of Medical Sciences, University of Fukui

23-3 Shimoaizuki, Matsuoka, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan

Telephone: +81-776-61-3111 ext 2313, FAX: +81-776-61-8129

E-mail: yohshima@u-fukui.ac.jp
Abstract

Background: Allergen-specific immunotherapy has been anticipated to be a disease-modifying therapy for food allergies. We previously reported that CD8\(^+\) regulatory T cells may prevent antigen-sensitized mice from developing allergic diarrhea. Because oligomannose-coated liposomes (OML) have been shown to induce MHC class I-restricted CD8\(^+\) T cell responses, we analyzed the adjuvant activities of OML for inducing regulatory CD8\(^+\) T cells and mucosal tolerogenic responses in allergen-sensitized mice.

Methods: BALB/c mice that were previously sensitized to ovalbumin (OVA) were intranasally immunized with OVA-encased in OML (OVA-OML) or OVA-encased in non-coated liposomes (OVA-NL). We assessed allergic diarrhea induced by oral OVA administration, OVA-specific immunoglobulin production, and cytokine production in the intestines and mesenteric lymph nodes (MLNs).

Results: Intranasal immunization with OVA-OML, but not OVA-NL, suppressed the development of allergic diarrhea. This was associated with in vitro Ag-induced IL-10 production and the in vivo expansion of CD8\(^+\)CD28\(^-\) and CD4\(^+\)CD25\(^+\)Foxp3\(^+\) T cell populations among mesenteric lymph node mononuclear cells, and was significantly ablated by anti-SIGNR1 or anti-CR3 mAbs. Up-regulation of serum OVA-specific IgE
was suppressed, whereas OVA-specific IgG1, IgG2a, and soluble IgA production were
enhanced by intranasal administration of OVA-OML. Adoptive transfer of CD8^+CD28^-
T cells but not CD8^+CD28^+ T cells from the MLNs of OVA-OML-treated mice
ameliorated the development of diarrhea.

**Conclusion:** These results suggest that intranasal immunization with Ag-encased OML
may be an effective immunotherapy for food allergies, as it induces a subset of
regulatory CD8^+ T cells as well as CD4^+CD25^+Foxp3^+ T cell and modulates humoral
immune responses in allergen-sensitized mice.

**Key Words:** food allergy; liposome; mouse model; oligomannose; regulatory T cells

**Word count:** 2484
Food allergy is often associated with aberrant Th2-type immune responses and the breakdown of oral tolerance to food antigens (Ags). Recently, a number of immunotherapeutic approaches have been reported that focused on the induction of oral tolerance (1, 2). Classical allergen-specific immunotherapy for food allergy by delivering Ag via the subcutaneous route can result in severe adverse reactions. Thus, appropriate Ag delivery routes and systems are needed to improve Ag targeting to the mucosal immune system.

The reduction of food allergy symptoms by immunotherapy or by outgrowing them has been hypothesized to be mediated by the induction of regulatory T cells, as well as by a shift from a Th2 to a Th1 response, and/or by the balance between allergen-specific IgE and IgG antibodies, which may regulate mast cell and basophil activities (3, 4). We recently demonstrated that inducible CD8\(^+\) T cells may prevent Ag-sensitized mice from developing allergic diarrhea (5). Thus, manipulating CD8\(^+\) regulatory T cells is anticipated to be a novel therapeutic strategy for food allergy.

Presentation of exogenous Ags on MHC class I molecules, termed cross-presentation, is essential for the induction of CD8\(^+\) T-cell responses (6-8). Several studies have demonstrated that Ag mannosylation or mannosylated Ag delivery systems, such as
mannosylated-liposomes, could enhance not only MHC class II-, but also MHC class I-restricted Ag presentation and T cell stimulation by targeting mannose receptors on APCs (9, 10). Recently, oral delivery of highly mannosylated Ag has been shown to selectively target dendritic cells in the lamina propria via specific ICAM-3 grabbing non-integrin-related 1 (SIGNR1) and, thereby, induce the generation of CD4\(^+\) type 1 regulatory T (Tr1)-like cells that expressed IL-10 and interferon-\(\gamma\) (11). However, incorporating new glycosylation sites by genetic engineering or by direct attachment of mannose residues to non-glycosylated Ags may compromise their inherent immunogenicity.

Kojima et al. (12) reported that liposomes coated with synthetic neo-glycolipids comprised of mannotriose and dipalmitoylphosphatidylcholine (oligomannose-coated liposomes; OML) induced a Th1-like immune response with cytotoxic T cells specific for Ags encased in the liposomes following subcutaneous or intraperitoneal administration (12, 13). Intranasal delivery of OML was shown to induce both mucosal and systemic immune responses (14). SIGNR1 acts as a receptor for the recognition of OML (15). These results led us to hypothesize that OML could be used as a mucosal adjuvant to induce regulatory CD8\(^+\) T cells, Tr1-type immunity, and mucosal immune responses.
The aim of this study was to determine whether intranasal administration of OML could induce mucosal tolerogenic responses in mice that had been previously sensitized to OVA, a model food Ag. Our results indicate that intranasal administration of OML induces regulatory CD8+ T cells and Ag-specific secretory IgA in localized tissues of OVA-sensitized mice and, thereby, ameliorates the development of allergic diarrhea.
Materials and methods

Food allergy animal models

BALB/c mice were bred under standard pathogen-free conditions. All animal experiments were performed in accordance with institutional guidelines as approved by the Animal Care Review Board of the University of Fukui. Six-week-old female mice were sensitized to OVA or ovomucoid (OM) (Sigma-Aldrich Co., St. Louis, MO) by intraperitoneal injection of 100 μg of OVA or OM in alum (Imject Alum, Thermo Scientific, Rockford, IL) on days -35 and -21. Beginning on day 0, the sensitized mice received challenges by oral gavage of 20 mg OVA or OM dissolved in 0.2 ml PBS every other day for up to 6 doses. Before each intragastric challenge, mice were deprived of food for 2 hours. Diarrhea was assessed visually and body temperature was monitored for up to 1 hour following intragastric challenge.

OVA-OML and treatments

OVA-encased in oligomannose-coated liposomes (OVA-OML) and control OVA-encased in non-coated naked liposomes (OVA-NL) were purchased from Bio Med Core Inc. (Yokohama, Japan). The OML were comprised of dipalmitoylphosphatidylcholine : cholesterol:
mannotriose-dopalmitoylphosphatidylethanolamine (10:10:1) with a particle size of 1 μm (13). OVA-OML, OVA-NL, or OVA PBS solution (20 μl/dose each), containing 0.2 μg OVA/dose, was administrated into the left side of the nose of sensitized mice by intranasal instillation over 5 minutes for up to 5 doses from days -14 to -10.

Anti-SIGNR1 mAb (ER-TR9) (AbD Serotec, Oxford, UK), or anti-complement receptor 3 (CR3) mAb (M1/70) (AbD Serotec), or control rat Ig (2 μg/dose) was intranasally administrated 5 minutes before each intranasal instillation of OVA-OML.

Adoptive transfer of primed CD8+ T cells

Total CD8+ T cells, and CD28+ and CD28- CD8+ T cell subsets were purified from mesenteric lymph nodes (MLNs) of OVA-sensitized and challenged mice using MACS CD8+ T cell Isolation Kits (Miltenyi Biotec GmbH, Bergish Gladbach, Germany) and a FACSCanto II (BD Biosciences). A total of 0.8 x 10^6 CD8+ T cells, CD28-CD8+ T cells, or CD28-CD8+ T cells per mouse were adoptively transferred into OVA-sensitized mice by intravenous injection on day -1.

Monoclonal antibodies and flowcytometry

Anti-mouse CD3, CD4, CD8, CD25, CD28, CD103, CD122, and CTLA-4 mAbs
were purchased from BD Biosciences. Cells were stained using standard procedures and analyzed with a FACSCalibur (BD Biosciences).

**Cell culture**

Twenty-four hours after the last OVA challenge, mononuclear cells from MLNs were isolated. Cells (1 x 10^5/well) were cultured either with medium alone (RPMI 1640 supplemented with 50 mM HEPES, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 x 10^-5 M 2-mercaptoethanol, and 10% heat inactivated fetal calf serum (Sigma-Aldrich Co.) or with OVA (1 mg/ml) for 72 h. Supernatants were collected for cytokine measurements.

**Cytokine and OVA-specific antibody measurements**

IL-4, IL-10, and IFN-γ in the culture supernatants were measured by a two-site sandwich ELISA, as described previously (5). Serum levels of OVA-specific IgG1, IgG2a, and IgE and the concentration of OVA-specific secretory IgA in intestinal lavage fluids, obtained by washing 10 cm of intestine with 1 ml of PBS, were determined by ELISAs, as described previously (5).
Real-time polymerase chain reaction

Total RNA was isolated from samples of the jejunum and mRNA levels were quantified as described previously (5). Results were expressed as relative units, which were calculated by the comparative Ct method.

Statistical analysis

Results are given as means ± standard errors of the mean. Comparisons of 2 groups used unpaired Student’s t-tests, unless an F-test showed that the variances were significantly different. When variances were significantly different, Welch’s test was used. Comparisons of the occurrences of diarrhea were made by Kaplan-Meier survival analysis. A p-value < 0.05 was considered statistically significant.
Results

Nasal immunization with OVA-OML alleviates allergic diarrhea

As previously described (5, 16, 17), the OVA- and OM-sensitized mice developed allergic diarrhea accompanied by hypothermia after repetitive intragastric OVA and OM challenges, respectively (Fig. 1B and 1C). Intranasal instillation of OVA-OML inhibited the development of allergic diarrhea and hypothermia in OVA-sensitized and challenged mice, but not in OM-sensitized and challenged mice, indicating that the effects of immunotherapy with OML is Ag-specific.

In the jejunum of OVA-sensitized mice, intragastric OVA challenges increased the infiltration of eosinophils and the mRNA expression of IL-4, IFN-γ, IL-10, and TGF-β with a Th2 dominant pattern and increased mucosal mast cell protease-1 (mmcp1) mRNA expression (Fig. 1D - F). Immunotherapy with intranasal instillation of OVA-OML significantly suppressed the accumulation of eosinophils and the mRNA up-regulations of mmcp1 and IL-4, while it marginally reduced the mRNA expression of IFN-γ, IL-10, and TGFβ1.

Oligomannose residues are essential for the adjuvant effects of OML.

We next asked whether the oligomannose residues on liposomes were critical for the
suppressive effects of intranasal instillation of OVA-OML. OVA-sensitized mice were
intranasally immunized with OVA entrapped in carbohydrate-uncoated, bare liposomes
(OVA-NL) or OVA alone. Intranasal instillation of OVA-NL or OVA alone did not
inhibit the development of allergic symptoms, the accumulation of eosinophils, and the
increases in IL-4 and mmcp1 mRNA expression in the jejunum (Fig. 2).

Intranasal immunization with OVA-OML modulates Ag-specific immunoglobulin
production.

Before OVA challenges there were no significant differences in the serum levels of
OVA-specific IgE, IgG1 and IgG2a Abs between OVA-OML-treated mice and untreated
mice (Fig. 3). After repetitive challenges, the serum OVA-specific IgE levels of
OVA-OML-treated mice were lower than those of untreated mice, whereas the serum
levels of OVA-specific IgG1 and IgG2a and the concentration of secretory
OVA-specific IgA in the intestinal lavage fluids of OVA-OML-treated mice were higher
than those of untreated mice.

OVA-OML treatment modifies the phenotype and function of MLN cells

Because MLNs play critical roles in the development of food allergy and oral
tolerance (17, 18), we analyzed in vitro OVA-induced cytokine production by MNL mononuclear cells purified from the mice after repetitive OVA challenges. Intranasal immunization with OVA-OML significantly increased the in vitro OVA-induced IL-10 production by MLN mononuclear cells, but did not significantly affect OVA-induced IL-4 and IFN-γ production (Fig. 4A).

To assess the expansion of regulatory T cell populations in MLNs after intranasal immunization with OVA-OML, we analyzed MLN T cell subsets. As shown in Fig 4B, the frequencies of CD4^+Foxp3^+ T cells, and CD8^+CD28^- T cells, but not that of CD8^+CD122^+T cells, or CD8^+CD103^+T cells among MLN T cells significantly increased in the intranasally-immunized mice compared with non-immunized mice.

Adoptive transfer of MLN CD8^+ T cells alleviates allergic diarrhea.

To determine whether the MLN CD8^+ T cells functioned as regulatory T cells in vivo to inhibit the development of allergic diarrhea, mononuclear cells or CD8^+ T cells that were purified from OVA-OML-treated or untreated mice after repetitive OVA challenges were adoptively transferred to other OVA-sensitized mice. As shown in Fig 5, adoptive transfer of CD8^+ T cells from OVA-OML-treated mice, but not from untreated mice, significantly inhibited the development of diarrhea and hypothermia. These cells
also abrogated the up-regulation of mmcp1 and IL-4 mRNA expression in the intestine, although to a lesser extent. Adoptive transfer of CD8\(^+\) T cells from OVA-OML treated mice slightly, but significantly, suppressed the up-regulation of serum levels of OVA-specific IgE and enhanced serum OVA-specific IgG2a levels, but did not affect OVA-specific secretory IgA levels in intestinal lavage fluids (Figure 5).

To characterize the phenotype of CD8\(^+\) T cells with these suppressive effects, CD28\(^-\)CD8\(^+\) T cells were purified from MLNs of OVA-OML-treated mice using fluorescence-activated cell sorting. CD28\(^-\)CD8\(^+\) T cells were responsible for the suppressive effects on the allergic symptoms \textit{in vivo}, whereas CD28\(^+\)CD8\(^+\) T cells had little, if any, effect (Figure 6A-C).

\textit{SINGNR1 and CR3 are necessary for the therapeutic effects of OVA-OML.}

Since CR3 is known to cooperatively act with SINGR1 as a receptor for recognition and uptake of OMLs (15), we administered anti-SIGNR1 mAb or anti-CR3 mAb to OVA-sensitized mice before intranasal instillation of OVA-OML. The suppressive effects of intranasal instillation of OVA-OML were significantly ablated by anti-SIGNR1 mAb or anti-CR3 mAb (Figure 6D-F).
In the present study, we examined a novel therapeutic approach for food allergy using intranasal immunization of Ag entrapped in OML. The mechanisms of intranasal immunotherapy with OML appeared to be due (1) to the induction of regulatory CD8\(^+\) T cells, primarily among the CD28\(^-\)CD8\(^+\) T cell population, as well as CD4\(^+\)CD25\(^+\)Foxp3\(^+\) T cells and (2) to the modulation of humoral immune responses, including enhanced Ag-specific IgGs and secretory IgA production and suppressed up-regulation of Ag-specific IgE. SIGNR1 and CR3 are involved in the therapeutic effects of OVA-OML.

Various phenotypes of regulatory CD8\(^+\) T cells have been identified in different experimental systems (19, 20). In an experimental inflammatory bowel disease model, naturally occurring CD8\(^+\)CD28\(^-\)CD122\(^-\) regulatory T cells inhibited IFN-\(\gamma\) production by colitogenic CD4\(^+\) T cells and prevented colitis. (21). Intraperitoneal application of zwitterionic capsular polysaccharides of commensal bacteria increased CD8\(^-\)CD28\(^-\) T cells, which exhibited immunosuppressive properties on CD4\(^+\) T cells (22). The expanded CD8\(^-\)CD28\(^-\) T cell population found in the MLNs of OVA-OML immunized mice displayed a more robust regulatory function than did the CD8\(^+\)CD28\(^+\) T cell population in vivo, suggesting that the therapeutic effects of OML instillation could be
attributed, in part, to the induction of CD8⁺CD28⁻ regulatory T cells.

Treatment of peanut Ag-sensitized mice with a Chinese herbal medicine preparation (FAHF-2) prevented oral Ag-challenge-induced anaphylaxis (23). The inhibitory effect of FAHF-2 was mediated by increased IFN-γ production by CD8⁺ T cells. By comparison, we recently demonstrated that the IL-10-producing capability of CD8⁺ T cells and IL-10 expression by MLNs were associated with alleviating allergic diarrhea (5). IL-10 and TGF-β play essential roles in the suppressive activities of CD8⁺CD28⁻ regulatory T cells (21, 22). Takayama et al. (24) reported that IL-10-producing CD4⁺CD25⁺Foxp3⁺ T cells in Peyer’s patches inhibited the development of allergic diarrhea. Intranasal immunization with OVA-OML increased the percentages of CD4⁺CD25⁺Foxp3⁺ T cells and CD28⁻CD8⁺ T cells, and enhanced Ag-induced IL-10 production by MLN cells in vitro. IL-10 rather than IFN-γ production by MLNs may be involved in the therapeutic effects of OVA-OML immunization.

It is well known that the production of IgG1 and IgE is regulated by a Th2 response, whereas IgG2a production is regulated by a Th1 response (25). Immunotherapy with OVA-OML enhanced the up-regulation of both OVA-specific IgG2a and IgG1, indicating no appreciable shift from Th2- to Th1-dominant humoral responses. IL-21R⁻/⁻ mice exhibit impaired Ag-specific IgG1 production and augmented
Ag-specific IgE production (26). Although IL-21 was not detected in the supernatants of OVA-stimulated MLN mononuclear cells (data not shown), IL-21 might explain the discordant IgE and IgG1 responses in OVA-OML-treated mice. Schmitz et al. (27) reported that immunotherapy with recombinant cat allergen displayed on virus-like particles induced allergen-specific IgG1 production and abolished an IgE memory response in allergen-sensitized mice and that the allergen-specific IgG antibodies alleviated allergic symptoms in FcγRIIb-dependent and independent manners. The enhanced OVA-specific IgG1 and IgG2a production might also account for the therapeutic effects of OVA-OML immunotherapy.

Actively tolerized mice were found to have higher fecal Ag-specific IgA titers than anaphylactic mice (28). Adoptive transfer of CD8⁺ T cells from OVA-OML immunized mice failed to induce OVA-specific secretory IgA production and tended to exhibit weaker inhibitory effects on the development of food allergy than OVA-OML immunization itself (Fig. 2 and Fig. 5). Although this might have been due to the small number of transferred CD8⁺ T cells, secretory IgA may also play a protective role against the development of food allergy by preventing the uptake of food Ag with intact epitopes from mucosal surfaces.

In summary, our results demonstrate that Ag entrapped in OML has potential uses for
treatment established allergies and at least two different mechanisms may be involved:

induction of regulatory T cells and modulation of humoral immunity. It is difficult to
determine the relative contributions of CD8^+CD28^- and CD4^+CD25^-Foxp3^+ T cells and
humoral immunity to OML-induced suppression of food allergic symptoms. Multiple
mechanisms may act synergistically suppress of allergic symptoms. Because OML are
comprised of innocuous materials, are ubiquitously distributed throughout the body (29),
they could be useful as an immunotherapy adjuvant and Ag delivery system for food
allergy.

Acknowledgments: This project was supported by research grants from the Ministry of
Health, Labor and Welfare, Japan.

Conflict of interest: The authors declare that they have no conflict of interest.

Author contribution: A.K. and H.S. contributed equally to this work. Each named
author in this report contributed to its content either through being integral to the
experimental planning and/or its implementation at the bench.
References


18. du Pre MF, Samsom JN. Adaptive T-cell responses regulating oral tolerance to


Figure legends

Figure 1. Intranasal immunization with OVA-OML ameliorates the development of allergic diarrhea. (A) Experimental protocol. (B) Diarrhea occurrence following repetitive challenges and (C) body temperature changes after the last challenge in non-immunized, OVA-sensitized mice (open circles), non-immunized, OM-sensitized mice (open squares), OVA-OML-immunized, OVA-sensitized mice (closed circles), or OVA-OML-immunized, OM-sensitized (closed squares); n = 12/group. (D) Jejunum of negative control non-challenged, positive control non-immunized or OVA-OML immunized OVA-sensitized mice. (E) Numbers of eosinophils and (F) cytokine and mmp1 mRNA expression in the jejunum of positive control non-immunized mice (filled bars) and OVA-OML immunized mice (hatched bars) after the last challenge. Results for non-sensitized mice (open bars) and sensitized mice (dotted bars) without challenges are negative controls. Results are means ± SE (n = 6) and are representative of 3 independent experiments. Kaplan-Meier survival analysis, unpaired Student’s t-tests, and Welch’s tests were used for statistical analysis. *p < 0.05, **p < 0.01

Figure 2. Intranasal immunization with OVA-NL or OVA alone fails to suppress the development of allergic diarrhea and hypothermia. (A) Experimental protocol. (B)
Diarrhea occurrence following repetitive challenges and (C) body temperature changes after the last challenge in non-immunized mice (open circles) or in mice immunized with OVA alone (closed squares), OVA-NL (open squares), or OVA-OML (closed circles); n = 12/group. (D) IL-4, (E) mmcp1 mRNA expression, and (F) numbers of infiltrated eosinophils in the jejunum of non-immunized mice or mice immunized with OVA alone, OVA-NL, or OVA-OML after challenges. Results for non-sensitized or sensitized mice without challenges are negative controls. Results are means ± SE (n = 6) and are representative of 3 independent experiments. Kaplan-Meier survival analysis, unpaired Student’s t-tests and Welch’s tests were used for statistical analysis. *p< 0.05, **p< 0.01

Figure 3. Intranasal immunization with OVA-OML modulates Ag-specific immunoglobulin production. Serum OVA-specific (A) IgE, (B) IgG1 and (C) IgG2a concentrations of non-immunized (open circles) or OVA-OML-immunized mice (closed circles) were determined at pre-immunization, and at pre- and post-challenges. (D) OVA-specific secretory IgA in the intestinal lavage fluid was determined after challenges. Results are means ± SE (n = 6) and are representative of 3 independent experiments. Unpaired Student’s t-tests and Welch’s tests were used for statistical
Figure 4. Intranasal immunization with OVA-OML enhances OVA-induced IL-10 production by MLN mononuclear cells in vitro and alters MLN T cell populations. (A) *p< 0.05

In vitro OVA-induced IL-4, IFN-γ, and IL-10 production by MLN mononuclear cells purified from non-immunized (open bars) and OVA-OML-immunized (filled bars) mice after challenges. Results are means ± SE (n = 6) and are representative of 3 independent experiments. Unpaired Student’s t-tests were used for statistical analysis. *p< 0.05 (B)

Results for cell surface phenotypes of MLN T cells from non-immunized and OVA-OML-immunized mice after challenges were obtained by gating on CD3+ cells. Indicated values are the percentages of each subset among MLN T cells. Results of one representative experiment of 6 are shown.

Figure 5. Adoptive transfer of MLN CD8+ T cells from OVA-OML-treated mice ameliorates allergic diarrhea. (A) Experimental protocol. (B) Diarrhea occurrence following repetitive challenges and (C) body temperature change after the last challenge in non-transferred mice (open circles), mice with CD8+ T cells transferred from non-immunized controls (open squares), and OVA-OML immunized mice (closed
(D) IL-4 and (E) mmcp1 mRNA expression in the jejunum, serum OVA-specific (F) IgE, (G) IgG1, and (H) IgG2a concentrations, and (I) OVA-specific secretory IgA in the intestinal lavage fluid from non-transferred mice or from mice with MLN CD8$^+$ T cells transferred from non-immunized or OVA-OML immunized mice. mRNA expression for non-sensitized and sensitized mice without challenges are negative controls. Results are means ± SE (n = 6) and are representative of 3 independent experiments. Kaplan-Meier survival analysis, unpaired Student’s t-tests, and Welch’s tests were used for statistical analysis. *$p<0.05$

Figure 6. Adoptive transfer of MLN CD28$^-$CD8$^+$ T cells but not CD28$^+$CD8$^+$ T cells ameliorates allergic diarrhea. (A) CD28$^-$CD8$^+$ T cells and CD28$^+$CD8$^+$ T cells were purified from MLNs mononuclear cells. (B) Diarrhea occurrence following repetitive challenges and (C) body temperature change after the last challenge in non-transferred mice (open circles), or in mice with CD28$^-$CD8$^+$ T cells (closed squares) or CD28$^+$CD8$^+$ T cells (open squares) (0.8 x 10⁶/mouse) transferred from OVA-OML immunized mice; n = 8/group. (D) Experimental protocol for anti-SIGNR1 and anti-CR3 mAb treatments (E) Diarrhea occurrence following repetitive challenges and (F) body temperature change after the last challenge in non-immunized mice (open circles), or in mice
pre-treated with control Ig (closed circles), anti-SIGNR1 mAb (open squares), or anti-CD11b mAb (closed squares); n = 12/group. Kaplan-Meier survival analysis was used for statistical analysis. * p< 0.05
Figure 1

A

Sensitization Immunization Ag challenge
Days -35 -21 -14 -10 0 10
OVA or OM + Alum i.p. OVA-OML i.n. OVA or OM garavage Euthanize

B

Diarrhea occurrence (%)

A B OVA/Non/OVA OVA/OML/OVA OM/Non/OM OM/OML/OM

C

Body temperature (°C)

D

Sensitized Non-immunized OVA-OML

E

Eosinophils (hpf)

F

Non-sensitized Sensitized No challenge Non-immunized OVA-OML

Log₂ (mRNA expression)

IL-4 IFN-γ IL-10

Log₂ (mRNA expression)

TGF-β1 mmp1
Figure 2

A

Sensitization Immunization Ag challenge

Days -35 -21 -14 -10 0 10

OVA + Alum i.p.

soluble OVA or OVA-NL or OVA-OML i.n.

OVA garbage Euthanize

B

Diarrhea occurrence (%)

0 20 40 60 80 100

1 2 3 4 5 6

Number of Ag challenge

C

Body temperature (°C)

36 37 38 39

0 15 30 45 60

Time after challenge (min)

-14 0 10 11 12 13 14 15

Log2 (IL-4 mRNA expression)

Log2 (MMCP mRNA expression)

** *

D

Eosinophils (/hpf)

0 50 100 150 200

No challenge

-14 -13 -12 -11

Log2 (IL-4 mRNA expression)

* **

Non-Sensitized Sensitized Non-immunized

Non-Sensitized Sensitized Non-immunized

soluble OVA OVA-NL OVA-OML

E

Immunization

soluble OVA or OVA-NL or OVA-OML i.n.

F

Euthanize

No challenge

-14 -13 -12 -11

Log2 (IL-4 mRNA expression)

* **

Non-Sensitized Sensitized Non-immunized

Non-Sensitized Sensitized Non-immunized

soluble OVA OVA-NL OVA-OML
Figure 3

A

B

C

D

IgE (AU/ml)

IgG1 (AU/ml)

IgG2a (AU/ml)

IgA (AU/ml)

Pre-immunization

Pre-challenge

Post-challenge

Pre-immunization

Pre-challenge

Post-challenge

Pre-immunization

Pre-challenge

Post-challenge

Non-immunized

OVA-OML

* * *
Figure 4

A

B

**Non-Immunized**

- **CD4**
  - OVA-OML: 4.1
  - **CD28**: 1.7
  - **CD122**: 4.6
  - **Foxp3**: 8.5

- **CD4**
  - OVA-OML: 8.7
  - **CD28**: 2.2
  - **CD122**: 0.8

**OVA-OML**

- **CD4**
  - Non-Immunized: 6.6
  - OVA-OML: 4.8
  - **CD25**: 8.8
  - **Foxp3**: 4.8

- **CD4**
  - Non-Immunized: 4.1
  - OVA-OML: 8.7
  - **CD25**: 8.8
  - **Foxp3**: 8.5

- **CD8**
  - Non-Immunized: 2.2
  - OVA-OML: 0.8
  - **CD103**: 8.5
  - **CD122**: 4.1

- **CD8**
  - Non-Immunized: 1.7
  - OVA-OML: 4.1
  - **CD103**: 8.5
  - **CD122**: 4.1
Figure 5

A) Sensitization Immunization Ag challenge
   Days -47 -33 -26 -22 -12 -2 -1
   OVA + Alum i.p. OVA-OML i.n. OVA garvage
   OVA + Alum i.p.
   OVA garvage
   Euthanize

B) Diarrhea occurrence (%)
   Number of Ag challenge
   Control CD8 OML CD8
   Non-transferred control-CD8

C) Body temperature (°C)
   Time after challenge (min)
   Control CD8 OML CD8
   Non-transferred

D) Log2 (mRNA expression)
   No challenge
   Control CD8 OML CD8
   Non-transferred

E) Log2 (mRNA expression)
   No challenge
   Control CD8 OML CD8
   Non-transferred

F) IgE (AU/ml)
   Non-transferred Control CD8 OML CD8

G) IgG1 (AU/ml)
   Non-transferred Control CD8 OML CD8

H) IgG2a (AU/ml)
   Non-transferred Control CD8 OML CD8

I) IgA (AU/ml)
   Non-transferred Control CD8 OML CD8
Figure 6

A

SSC
FSC
CD8
CD3
CD8
CD28

B

Diarrhea occurrence (%)

Number of Ag challenge

C

Body temperature (°C)

Time after challenge (min)

D

Sensitization
Immunization
Ag challenge

Days

-35
-21
-14
-10
0
10
11

OVA + Alum i.p.
OVA-OML + control Ig
OVA garvage
Euthanize

or anti-SIGNR1 mAb
or anti-CR3 mAb
i.n.

E

Diarrhea occurrence (%)

Number of Ag challenge

F

Body temperature (°C)

Time after challenge (min

- Non-transferred
- CD28posi
- CD28nega

- Non-immunized
- control Ig
- anti-SIGNR1 mAb
- anti-CR3 mAb